Small Molecules that Correct RNA Splicing

At Skyhawk Therapeutics we use proprietary structural, kinetic, and computational models to invent small molecules that correct splicing in RNA, targeting some of the world's most intractable diseases

PARTNERS

IN THE NEWS

Celgene execs shell out $92M cash for a pair of R&D deals that

will fit perfectly in their new home at Bristol-Myers

Celgene is shelling out $80 million in a cash upfront to add oncology, immuno-oncology and autoimmune diseases to the initial roundup of neurological targets mapped early in Skyhawk’s existence.

BOSTINNO

The 20 Startups to Watch in Boston in 2020

Based on factors like funding, partnerships, awards, technology licenses and more, we've worked to identify the startups that are on the precipice of something big. These companies, we think, will be making major moves to kick off the new Roaring 20s.

BIOCENTURY

Skyhawk’s $80M Celgene deal expands remit to autoimmune

In Skyhawk’s fifth deal of the year, the company is moving into a new therapeutic area and adding $80 million to its cash reserve. Skyhawk partnered with Celgene to discover and develop small molecules for autoimmune disease and cancer against hard-to-drug targets that have been clinically validated, or genetically associated with a disease.

C&EN

C&EN’s 2019 10 Start-Ups to Watch

Skyhawk Therapeutics: Drugging RNA splicing with small molecules to treat disease

WHAT WE DO

Our proprietary small molecule platform targets accelerates the discovery and development of drugs that correct RNA mis-splicing across a broad range of disease types:

ONCOLOGY

NEUROLOGY

INFLAMMATORY

INFECTIOUS

RARE

NEUROMUSCULAR

& METABOLIC

LEARN MORE